NCT03982030

Dalbavancin Outpatient Pilot

An Open-label, Pilot Clinical Trial of Dalbavancin for the Treatment of Susceptible Gram-positive Infections Requiring Prolonged Intravenous Antibiotic Therapy

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Wake Forest University Health Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research is to determine if a new antibiotic called dalbavancin will work to treat and cure certain infections while reducing the need for daily antibiotics by vein.

Detailed description

A phase 4, single-center, pilot open-label trial assessing the safety and efficacy of dalbavancin in the outpatient therapy of susceptible gram-positive infections requiring prolonged intravenous therapy.

Conditions

• Gram-Positive Bacterial Infections
• Soft Tissue Infections

Interventions

Type	Name	Description
DRUG	Dalbavancin	Dalbavancin 1.5g IV at day 0, day 8-10

Timeline

• Start date: 2023-04-01
• Primary completion: 2025-04-01
• Completion: 2025-07-01
• First posted: 2019-06-11
• Last updated: 2023-05-03

Regulatory

• FDA-regulated drug study